Optimizing treatment for kids with JIA in remission
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children between 2 and 18 years old with a type of arthritis called JIA.
- Joint inflammation has been quiet (inactive disease) for at least 12 months.
- Eye inflammation (uveitis) has been quiet for at least 2 years.
- On stable doses of methotrexate and a TNF inhibitor medicine for at least 6 months.
- No use of steroid medicines for arthritis in the past year.
- No other serious health problems that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
This study looks at how to measure treatment success in children with juvenile idiopathic arthritis (JIA), lupus (SLE), or fibromyalgia (FM). It may help doctors track symptoms more reliably over time.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This trial tests whether a special diet can help children and teens with juvenile arthritis. If you join, you will follow the diet and provide stool samples so the researchers can see how it affects your gut and arthritis.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.